Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VYNE Therapeutics Inc.    VYNE

VYNE THERAPEUTICS INC.

(VYNE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/19/2021 Date
1.65(c) 1.63(c) 1.65(c) 1.67(c) 1.78 Last
1 319 182 1 038 283 1 269 878 1 571 494 3 844 624 Volume
+1.85% -1.21% +1.23% +1.21% +6.59% Change
More quotes
Financials (USD)
Sales 2020 21,9 M - -
Net income 2020 -206 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,87x
Yield 2020 -
Sales 2021 61,9 M - -
Net income 2021 -79,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,98x
Yield 2021 -
Capitalization 280 M 280 M -
Capi. / Sales 2020 12,8x
Capi. / Sales 2021 4,53x
Nbr of Employees 40
Free-Float -
More Financials
Company
Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing... 
Sector
Calendar
-
More about the company
Notations Surperformance© of VYNE Therapeutics Inc.
Trading Rating : Investor Rating :
More Ratings
All news about VYNE THERAPEUTICS INC.
01/07VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
01/05VYNE THERAPEUTICS : to Present at the LifeSci Partners 10th Annual Healthcare Co..
AQ
2020VYNE THERAPEUTICS : Completes End-of-Phase 2 Meeting With FDA for FCD105 to Trea..
MT
2020VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for ..
GL
2020VYNE THERAPEUTICS : to Join Nasdaq Biotechnology Index
MT
2020VYNE THERAPEUTICS : Added to Nasdaq Biotechnology Index
AQ
2020VYNE THERAPEUTICS : Wins US Patent for Acne Treatment Amzeeq
MT
2020VYNE THERAPEUTICS : Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (mino..
AQ
2020VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data f..
GL
2020VYNE THERAPEUTICS : to Present at the 32nd Annual Piper Sandler Healthcare Confe..
AQ
2020VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conf..
GL
2020VYNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
2020VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K..
AQ
2020Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 EPS $-0.13, vs. Street Est o..
MT
2020Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Revenue $3.3M, vs. Street ..
MT
More news
News in other languages on VYNE THERAPEUTICS INC.

- No features available -

More news
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 5,93 $
Last Close Price 1,67 $
Spread / Highest target 499%
Spread / Average Target 255%
Spread / Lowest Target 79,6%
EPS Revisions